Fintel reports that on June 6, 2025, Scotiabank upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Sector ...

The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy ...

The Platform Technology Designation, which predates the current FDA leadership, is designed to streamline the drug ...

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have added about 7.7% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

Sarepta Therapeutics’ gene therapy to treat limb girdle muscular dystrophy type 2E/R4 gets US FDA platform technology designation: Cambridge, Massachusetts Friday, June 6, 2025, ...

US rare disease meds developer Sarepta Therapeutics (Nasdaq: SRPT) revealed that its rAAVrh74 viral vector used in the ...

Explore Sarepta Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for SRPT. Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade ...

RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that ...

Shares of Sarepta Therapeutics advanced after the company said it has received the go-ahead from U.K. regulators to keep dosing in a study of its Elevidys treatment for Duchenne muscular dystrophy.

The latest analyst rating for Sarepta Therapeutics (NASDAQ:SRPT) was provided by HC Wainwright & Co., and Sarepta Therapeutics reiterated their neutral rating. The last upgrade for Sarepta ...